MX2021001804A - Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm. - Google Patents
Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.Info
- Publication number
- MX2021001804A MX2021001804A MX2021001804A MX2021001804A MX2021001804A MX 2021001804 A MX2021001804 A MX 2021001804A MX 2021001804 A MX2021001804 A MX 2021001804A MX 2021001804 A MX2021001804 A MX 2021001804A MX 2021001804 A MX2021001804 A MX 2021001804A
- Authority
- MX
- Mexico
- Prior art keywords
- smarca2
- compositions
- urea compounds
- atpase inhibitors
- brm
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
Se proporciona un compuesto de Fórmula (I), o una sal farmacéuticamente aceptable del mismo, que ha demostrado ser útil para el tratamiento de una enfermedad o un trastorno mediados por BRM y/o mediados por BRG1: (ver Fórmula) Fórmula (I) en donde R1 a R6 son como se define en la presente descripción.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862765138P | 2018-08-17 | 2018-08-17 | |
PCT/IB2019/056847 WO2020035779A1 (en) | 2018-08-17 | 2019-08-12 | Urea compounds and compositions as smarca2/brm atpase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021001804A true MX2021001804A (es) | 2021-04-19 |
Family
ID=68072895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021001804A MX2021001804A (es) | 2018-08-17 | 2019-08-12 | Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm. |
Country Status (20)
Country | Link |
---|---|
EP (2) | EP4219488A1 (es) |
JP (1) | JP7328323B2 (es) |
KR (1) | KR20210047313A (es) |
CN (1) | CN112585136A (es) |
AU (1) | AU2019322325B2 (es) |
BR (1) | BR112021002632A2 (es) |
CA (1) | CA3107097A1 (es) |
CY (1) | CY1126039T1 (es) |
DK (1) | DK3837256T3 (es) |
ES (1) | ES2946060T3 (es) |
FI (1) | FI3837256T3 (es) |
HR (1) | HRP20230477T1 (es) |
HU (1) | HUE061963T2 (es) |
LT (1) | LT3837256T (es) |
MX (1) | MX2021001804A (es) |
PL (1) | PL3837256T3 (es) |
PT (1) | PT3837256T (es) |
RS (1) | RS64238B1 (es) |
SI (1) | SI3837256T1 (es) |
WO (1) | WO2020035779A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021512166A (ja) | 2018-01-30 | 2021-05-13 | フォグホーン セラピューティクス インコーポレイテッドFoghorn Therapeutics Inc. | 化合物及びその使用 |
AU2021213811A1 (en) | 2020-01-29 | 2022-07-28 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
CN112979646B (zh) * | 2021-03-08 | 2022-01-14 | 北京富龙康泰生物技术有限公司 | 一种咪唑并吡啶类衍生物 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
GB9823873D0 (en) * | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
JP2002532415A (ja) | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Mek阻害剤による関節炎の治療 |
US7217722B2 (en) * | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
EE05450B1 (et) | 2000-07-19 | 2011-08-15 | Warner-Lambert Company | 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine |
EP2308861B1 (en) | 2002-03-08 | 2017-03-01 | Eisai R&D Management Co., Ltd. | Macrocyclic compounds useful as pharmaceuticals |
PT3000810T (pt) | 2002-03-13 | 2017-10-25 | Array Biopharma Inc | Derivados de benzimidazole alquilado n3 como inibidores de mek |
JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
MX2008002114A (es) | 2005-07-21 | 2008-04-17 | Ardea Biosciences Inc | Inhibidores de n-(arilamino)-sulfonamida de mek. |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
US8455513B2 (en) * | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
ES2439705T3 (es) | 2007-10-25 | 2014-01-24 | Genentech, Inc. | Proceso para la preparación de compuestos de tienopirimidina |
MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
-
2019
- 2019-08-12 FI FIEP19779145.2T patent/FI3837256T3/fi active
- 2019-08-12 CN CN201980054231.1A patent/CN112585136A/zh active Pending
- 2019-08-12 HU HUE19779145A patent/HUE061963T2/hu unknown
- 2019-08-12 CA CA3107097A patent/CA3107097A1/en active Pending
- 2019-08-12 AU AU2019322325A patent/AU2019322325B2/en active Active
- 2019-08-12 BR BR112021002632-0A patent/BR112021002632A2/pt unknown
- 2019-08-12 ES ES19779145T patent/ES2946060T3/es active Active
- 2019-08-12 HR HRP20230477TT patent/HRP20230477T1/hr unknown
- 2019-08-12 WO PCT/IB2019/056847 patent/WO2020035779A1/en unknown
- 2019-08-12 PT PT197791452T patent/PT3837256T/pt unknown
- 2019-08-12 DK DK19779145.2T patent/DK3837256T3/da active
- 2019-08-12 JP JP2021507613A patent/JP7328323B2/ja active Active
- 2019-08-12 LT LTEPPCT/IB2019/056847T patent/LT3837256T/lt unknown
- 2019-08-12 SI SI201930542T patent/SI3837256T1/sl unknown
- 2019-08-12 EP EP23160099.0A patent/EP4219488A1/en active Pending
- 2019-08-12 MX MX2021001804A patent/MX2021001804A/es unknown
- 2019-08-12 EP EP19779145.2A patent/EP3837256B1/en active Active
- 2019-08-12 RS RS20230377A patent/RS64238B1/sr unknown
- 2019-08-12 KR KR1020217007586A patent/KR20210047313A/ko active Search and Examination
- 2019-08-12 PL PL19779145.2T patent/PL3837256T3/pl unknown
-
2023
- 2023-06-02 CY CY20231100266T patent/CY1126039T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CY1126039T1 (el) | 2023-11-15 |
KR20210047313A (ko) | 2021-04-29 |
AU2019322325B2 (en) | 2022-01-20 |
JP2021534147A (ja) | 2021-12-09 |
US20210323956A1 (en) | 2021-10-21 |
HUE061963T2 (hu) | 2023-09-28 |
PT3837256T (pt) | 2023-05-23 |
PL3837256T3 (pl) | 2023-07-10 |
FI3837256T3 (fi) | 2023-05-15 |
AU2019322325A1 (en) | 2021-02-18 |
BR112021002632A2 (pt) | 2021-05-11 |
EP4219488A1 (en) | 2023-08-02 |
EP3837256A1 (en) | 2021-06-23 |
DK3837256T3 (da) | 2023-05-30 |
JP7328323B2 (ja) | 2023-08-16 |
HRP20230477T1 (hr) | 2023-07-21 |
CA3107097A1 (en) | 2020-02-20 |
LT3837256T (lt) | 2023-06-12 |
ES2946060T3 (es) | 2023-07-12 |
SI3837256T1 (sl) | 2023-07-31 |
RS64238B1 (sr) | 2023-06-30 |
CN112585136A (zh) | 2021-03-30 |
EP3837256B1 (en) | 2023-03-08 |
WO2020035779A1 (en) | 2020-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501326A1 (en) | Tgf-� inhibitors | |
MX2023002006A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
MX2017014613A (es) | Compuestos de bencimidazol e imadazopiridin-carboximidamida que tienen actividad como inhibidores de indolamina 2,3-dioxigenasa. | |
MX2016016516A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
MX2016016530A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
MX2021001804A (es) | Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm. | |
PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
PH12019501198A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
MX2020011317A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih. | |
MX2019010096A (es) | Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa. | |
MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
MX2020001157A (es) | Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). | |
MX2021012105A (es) | Compuestos de pirrol. | |
NZ746906A (en) | Oxaborole esters and uses thereof | |
MX2021015942A (es) | Composiciones y métodos para tratar trastornos del snc. | |
MX2021009971A (es) | Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos. | |
PH12020552185A1 (en) | N-substituted tetrahydrothienopyridine derivatives and uses thereof | |
JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
CR20210148A (es) | Compuestos de isoxazol carboxamida y usos de los mismos | |
MX2021014458A (es) | Compuestos triciclicos. | |
WO2020096916A3 (en) | Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection | |
MX2020001412A (es) | Compuestos y métodos para tratar la hiperpotasemia. |